{
    "2021-06-28": [
        [
            {
                "time": "",
                "original_text": "先于KKR、高瓴，打通42万家“门店”，百洋医药如何打造千亿生意",
                "features": {
                    "keywords": [
                        "百洋医药",
                        "门店",
                        "千亿生意"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药零售"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "医药与健康护理行业信息点评：体内CRISPR基因编辑首个临床试验公布",
                "features": {
                    "keywords": [
                        "CRISPR",
                        "基因编辑",
                        "临床试验"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "医药行业周报：第五批国家集采报价结束 看好不受集采影响的高壁垒创新和服务赛道",
                "features": {
                    "keywords": [
                        "国家集采",
                        "高壁垒创新",
                        "服务赛道"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药制造",
                        "医疗服务"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "药明康德寻求出售2300万股药明巨诺股份",
                "features": {
                    "keywords": [
                        "药明康德",
                        "药明巨诺",
                        "股份出售"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "药明康德寻求出售2300万股药明巨诺股份 资产异常",
                "features": {
                    "keywords": [
                        "药明康德",
                        "药明巨诺",
                        "资产异常"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "新发现！Immunity揭示神药二甲双胍在新冠肺炎中的作用机制；罗氏诊断携手金橡医学，助力精准医疗的持续创新丨贝壳日报",
                "features": {
                    "keywords": [
                        "二甲双胍",
                        "新冠肺炎",
                        "精准医疗",
                        "罗氏诊断"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药",
                        "精准医疗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "通化东宝：目前申报的三靶点抑制剂产品已获临床试验批准书",
                "features": {
                    "keywords": [
                        "通化东宝",
                        "三靶点抑制剂",
                        "临床试验"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "明德生物：公司目前暂未与药明康德进行合作",
                "features": {
                    "keywords": [
                        "明德生物",
                        "药明康德",
                        "合作"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "医药市值一哥退居老三 恒瑞医药7个创新药获批上市",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "创新药",
                        "市值排名"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "恒瑞医药市值掉队年内蒸发1876亿 深陷“药品集采”困局欲借创新药突围 连续下跌",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "药品集采",
                        "创新药",
                        "连续下跌"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}